Feng Hao

机构：Beijing VDJBio (China) · ORCID：0000-0002-6057-1097

发表论文 79 篇 · 总被引 54 次 · h-index 3

代表论文

• The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026 · Cancer Discovery · 被引 2)
• Modest Effects of Intensive Blood Pressure–Lowering on Quality of Life in Patients at High Cardiovascular Risk (2025 · Journal of the American College of Cardiology · 被引 2)
• Abstract 5679: A novel approach for antibody affinity maturation using AI-driven mutation prediction (2025 · Cancer Research · 被引 2)
• Abstract 5981: Over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery (2025 · Cancer Research · 被引 1)
• Abstract 4189: CRISPR-edited cell lines targeting key molecular pathways: Accelerating the development of synthetic lethal therapeutics beyond PARP inhibitors (2025 · Cancer Research · 被引 1)
• Supplementary Table S3 from The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer (2026)